Key Findings
Onalabs, a Barcelona-based deep-tech company specializing in sweat-based biosensing technology, has announced the completion of a new funding round, securing over 9.3 million Euros. This significant capital injection will accelerate the industrialization and market expansion of its product lineup, including the ONASPORT sports performance monitor, and drive the clinical validation and regulatory approval for its medical device in development, ONAVITAL. This funding round is a crucial step for Onalabs in establishing its leadership in the non-invasive health monitoring market.
Technical/Clinical Details
Onalabs’ technology relies on analyzing sweat through wearable sensors applied directly to the skin, enabling non-invasive measurement of various physiological parameters. The currently available ONASPORT is designed for athletes and fitness enthusiasts, offering real-time tracking of lactate levels, hydration status, electrolyte loss, and sodium levels. This empowers users to accurately understand their physiological responses during exercise, aiding in performance optimization and mitigating risks like heatstroke. Concurrently, ONAVITAL, under development as a medical device, aims to continuously measure blood pressure, heart rate, oxygen saturation, and body temperature. Continuous monitoring of these vital signs is extremely important for chronic disease management, remote patient monitoring, and early disease detection. The newly secured funds will be utilized to accelerate the rigorous clinical trials for ONAVITAL and the process of obtaining regulatory approvals from international bodies such as the FDA and CE Mark.
Background & Context
The non-invasive health monitoring market is experiencing rapid expansion, driven by advancements in wearable technology and growing interest in preventive and personalized medicine. Sweat-based biosensors are particularly promising in this market, as they can provide continuous, real-time physiological data without the need for blood draws or other invasive procedures. Onalabs, with its innovative approach, targets a wide range of applications from sports performance optimization to clinical medical use. The funding exceeding 9.3 million Euros indicates strong investor confidence in the technology’s potential and market growth opportunities. The success of a Spanish-based company in such a deep-tech sector also holds significant implications for the European innovation ecosystem.
Strategic Significance & Outlook
With this latest funding, Onalabs can scale up production of ONASPORT and accelerate its global market expansion. This will enable more athletes and general consumers to benefit from personalized, data-driven strategies for performance improvement based on sweat analysis. More importantly, the expedited clinical validation and regulatory approval for ONAVITAL could establish a new standard for non-invasive continuous monitoring in the medical field. This medical device is expected to enhance patient convenience and improve chronic disease management outside hospital settings, contributing to overall healthcare system efficiency and cost reduction. Onalabs aims to redefine the future of health and wellness through its sweat-based biosensing technology.
Source: https://www.trendhunter.com/trends/noninvasive-health-monitoring-solution
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments